"But from a practical perspective, we have no direct control over the daily trading of the shares."
You actually do:
Too much gleaning over massive overspend on assets that did not yield good return via results. Lack of partnership or licensing deals or prospects. Guided timelines not met, chunky self awards, etc, etc.
External market conditions provided this company with excellent raise opportunities which they did capitalise on during July 2021 to their credit, and the valuation/share price during great money pump of 2021 not a good barometer of value, but certainly a little too much spend for assets and limited results thereafter in the past. $338 million of capital spent is a pretty beefy spend for its early clinical stages, and plenty of progress liabilities lie ahead with future success.
A low price and forward income streams from IMU, I couldn't resist buying Precision in the US. IMU over-paid for the asset - as they have others - and its valuation now more reflective of that, versus the silly exuberance of 2021/2:
Once you've provided a decent licensing or partnership deal Lesley and added some $$$ to the very consuming capital needs, you can start nearly blaming entirely external factors. Ironically I hold IMU, at this lowly value, for exactly that reason. After years of frustrating/killing long-term holders, I do think a partnership/deals will emerge in the next year. As stated. before, TG' Thera's deal with Precision a good indication of the potential.
IMU Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)